Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving Rituximab
Top Cited Papers
- 4 January 2001
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (1) , 68-69
- https://doi.org/10.1056/nejm200101043440120
Abstract
CD20 antigen is expressed on most B lymphocytes. Therefore, humanized monoclonal antibodies to CD20, especially rituximab, specifically kill lymphomatous and normal B lymphocytes by means of cytotoxicity and apoptosis.1 Few infections have been reported in recipients of rituximab. A lethal reactivation of hepatitis B virus (HBV) infection occurred in a patient who was treated with cyclophosphamide, doxorubicin, vincristine, and prednisone and rituximab.1 We describe a patient who had antibodies to hepatitis B surface antigen (anti-HBs) but not hepatitis B surface antigen (HBsAg) before rituximab therapy and in whom anti-HBs disappeared and hepatitis B developed.Keywords
This publication has 5 references indexed in Scilit:
- Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virusBone Marrow Transplantation, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- REACTIVATION OF HEPATITIS B AFTER TRANSPLANTATION IN PATIENTS WITH PRE-EXISTING ANTI-HEPATITIS B SURFACE ANTIGEN ANTIBODIESTransplantation, 1998
- Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawalJournal of Hepatology, 1998
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapyPublished by Elsevier ,1991